Clinical Trial Update: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis [Phase 1, Phase 2]

View source ↗

Summary

Ocugen's OCU400 is being studied in a Phase 1/2 trial to assess safety and efficacy in patients with Retinitis pigmentosa and Leber congenital amaurosis. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis
• Retinitis Pigmentosa

Drugs mentioned

• OCU400

Snippet

Sponsor: Ocugen | Conditions: Retinitis Pigmentosa, Leber Congenital Amaurosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING